Robert Goggin | GenomeWeb

Robert Goggin

Mar 20, 2015

Robert Goggin, who was elected to Vermillion's board in 2013 amid shareholder discontent, will be retiring from the board at the end of his current term, the company said in a document filed with the US Securities and Exchange Commission. 

He will not stand for reelection to the board during Vermillion's 2015 annual shareholders' meeting and told the company that his retirement is not the result of any disagreement with Vermillion. 

Googin was elected to the board two years ago as a candidate put forth by a trio of dissident shareholders that included himself in order to influence Vermillion's then-management team.

More Like This

Dec 02, 2016

Maria Chan

Personal Genome Diagnostics has appointed Maria Chan vice president of regulatory strategy. Chan will oversee all regulatory activities at PGDx and will help shape the company's strategy for moving products through regulatory processes. Chan previously served as director of the Division of Immunology & Hematology Devices at the Center for Devices & Radiological Health, in the US Food and Drug Administration's Office of In Vitro Diagnostics & Radiological Health. She also served as a scientific reviewer and team leader of immunology, genetics, and molecular diagnostic devices, and as associate division director for the immunology branch at the FDA. Prior to the FDA, Chan served in various positions at Children's National Health System, the George Washington University Medical Center, and the Johns Hopkins University School of Medicine.
Dec 02, 2016

Daniel J. Warmenhoven

Theranos has appointed Daniel J. Warmenhoven to its board of directors, effective immediately. Warmenhoven has served in various positions with many companies in the technology industry, including as CEO of NetApp and as executive chairman of the NetApp board of directors. He has also served as chairman, president, and CEO of Network Equipment Technologies, and has held senior management positions at Hewlett-Packard and IBM. He is currently a director on the boards of Bechtel Group and Palo Alto Networks. Warmenhoven is replacing retiring director Riley P. Bechtel, who is stepping down because of health issues. 

Theranos also announced that it will retire its Board of Counselors as part of an ongoing restructuring of its corporate advisory framework.

Dec 02, 2016

Hayden Jeffreys

ERBA Diagnostics has appointed Hayden Jeffreys as interim CEO, effective Jan. 1, 2017. The employment agreement of the company's current CEO Mohan Gopalkrishnan expires on Dec. 31. Jeffreys has served on ERBA's board of directors since May 31, and also serves as the commercial director for the molecular diagnostics division and as vice president of business development and strategy for ERBA Diagnostics Mannheim. He plans to continue in those capacities. Prior to joining ERBA Mannheim, Jeffreys served in a variety of positions for several diagnostics companies, including Lumora, Lab21 Healthcare, Invitron, Kronus, and Gen-Probe UK (now Hologic).

Nov 29, 2016

Catherine Ball

Ancestry has appointed Catherine Ball as Chief Scientific Officer. The consumer genomics firm promoted her from VP of Genomics and Bioinformatics, a job she's held since 2011. 

As CSO, Ball will lead initiatives to develop new technologies to analyze genetic data along with family relationship data.

Prior to joining Ancestry, Ball held appointments at the Stanford University School of Medicine in the Departments of Genetics and Biochemistry, where she led the Stanford Microarray Database. As part of her research, she contributed to the annotation of the Saccharomyces cerevisiae genome and has built genomic databases for yeast, Escherichia coli, and Mycobacterium tuberculosis.

Ball holds a doctorate in molecular biology from the University of California, Los Angeles and she was a postdoc at UC-Berkeley.

Nov 23, 2016

Amy Miller

Amy Miller, executive VP of the Personalized Medicine Coalition, will join the Society for Women's Health Research as its new CEO starting Jan. 3, 2017. 

SWHR has been advocating for greater inclusion of women in health research for more than 25 years. The organization's efforts were instrumental to the National Institutes of Health issuing guidelines requiring women be included in clinical research; to the passage of the 1993 NIH Revitalization Act, which mandated sex-based analysis in Phase III clinical trials; and to the US Food and Drug Administration putting out guidelines requiring women's participation in early drug efficacy studies. 

"We welcome Amy to lead SWHR at a critical crossroads in women’s health research," SWHR Founder Florence Haseltine said in a statement. "While we celebrate the many achievements in women’s health policy advocacy to date, we must continue to press for unlocking the mysteries in sex differences and how men and women are different when it comes to cures, treatments and prevention." 

Miller's tenure at PMC has primed her to lead SWHR. At PMC, she worked with stakeholders accross academia, industry, and governement to support policies that would spur devleopment and adoption of diagnostics and peronalized drugs that capitalize on biological differences among individuals. Previously, at the office of the Director of the National Institute of Mental Health, Miller worked to connect researchers, legislators, patients, and their families. She was also a fellow at the American Association for the Advancement of Science and domestic policy advisor to Senator Jay Rockefeller.

Nov 16, 2016

Marra Francis

Vermillion has appointed Marra Francis as chief medical officer. Francis is a board-certified obstetrician and gynecologist. She has served as a national speaker and key opinion leader for Myriad Genetics, as national speaker for Cord Blood registries, as an "Ask the Expert" contributor at, as a contributing physician to the Mommy MD Guide books and publications, and a medical affairs consultant for Vermillion. Francis has also served as both vice chair and chair of the Department of Obstetrics and Gynecology at Memorial Hermann The Woodlands Hospital.

Nov 16, 2016

Stephen Tang

OraSure Technologies has appointed Stephen Tang as chairman of its board of directors. Tang takes over from Douglas Watson, who served as chairman since March 2003. He has been a board member since April 2011, served as chairman of the compensation committee since May 2014, and is also a member of the nominating and corporate governance committee. Tang has now relinquished his position as chairman of the compensation committee, but will remain as a member of both committees while serving as chairman of the board.

Nov 15, 2016

Michael Dugan

Clinical Genomics has appointed Michael Dugan as its chief medical officer. Dugan previously served as president and CEO of MCDXI Medical Diagnostics, where he led clinical evaluation, strategic development and clinical education efforts for companies bringing diagnostic tests and related products to market. Before that, he was also senior vice president of clinical development and medical affairs at Exact Sciences, medical director at Quest Diagnostics' Nichols Institute, and vice president and laboratory director at Specialty Laboratories.

Nov 11, 2016

David Halverson

Protea Biosciences has appointed David Halverson as its President.

Halverson has served as Protea's VP and Chief Business Officer. Before joining Protea, he worked at Huntingdon Life Sciences in a number of roles, including head of European and US sales.

Nov 11, 2016

Brian Kim

LGC has appointed Brian Kim as managing director of genomics. Kim joins LGC from PerkinElmer, where he led the life sciences division. In that position he managed a global portfolio of various technologies and products ranging from instruments, reagents, service, and software.

Nov 10, 2016

Christian Henry

Wave Life Sciences has appointed Christian Henry to its board of directors and chair of its audit committee. Henry has over twenty years of leadership experience, ten of which was spent holding a variety of executive level positions at Illumina, including CFO, general manager of life sciences, general manager of genomic solutions, and most recently chief commercial officer. Prior to joining Illumina, he served as CFO of He has also he served as vice president of finance and corporate controller of Affymetrix, and held various positions at Nektar Therapeutics, Sugen, and Ernst & Young.

Nov 10, 2016

Catherine Dumur

Aurora Diagnostics has named Catherine Dumur as director of molecular and next-generation sequencing development. Aurora, which is headquartered in Palm Beach Gardens, Florida, focuses on anatomic pathology and cancer diagnostics. Previously, Dumur served as the associate director of molecular diagnostics in the pathology department at Virginia Commonwealth University. She will be responsible for development and ongoing performance of NGS molecular diagnostic assays, proficiency testing, quality control, quality improvement programs, and signing out clinical cases.

Nov 09, 2016

Jeff Elliott

Exact Sciences has appointed Jeff Elliott as CFO. He joined the company as vice president of business development and strategy in June and will begin his new role effective immediately. Before joining Exact Sciences, Elliott served as a senior research analyst at Robert W. Baird. Previously in his career, he worked in various positions at Walgreens and Cap Gemini Ernst & Young.

Nov 09, 2016

Genos Strategic Advisory Board

Genos has appointed George Church, Mina Radhakrishan, Alvin Roth, Dietrich Stephan, and Chris Tsakalakis to the company's strategic advisory board. Church's research was seminal in enabling the first consumer genome sequence in 1994. He is currently a professor genetics at Harvard Medical School, director of the Center for Computational Genetics, founder of, and a founding core member of Wyss Institute. Radhakrishan was the former head of product at Uber and a current startup advisor. She is also currently an entrepreneur-in-residence at Redpoint Ventures, special advisor at Cowboy Ventures, and a mentor to companies in the 500 Startups portfolio. Roth is a professor of economics at Stanford University and a 2012 Nobel Prize winner. Stephan is the chair of the department of human genetics at the University of Pittsburgh, founding chairman of the neurogenomics department at Translational Genomics Research Institute, and founder of Navigenics. Tsakalakis is currently an entrepreneur-in-residence at Benchmark Capital, and has previously was president of the online ticket marketplace StubHub for eight years.

Nov 08, 2016

Jill Hagenkord

Color Genomics has appointed Jill Hagenkord as chief medical officer. Hagenkord is a board-certified molecular genetic pathologist with a mix of clinical and industry experience, and is also currently an assistant professor at the University of California, San Francisco. Prior to joining Color, she was chief medical officer of 23andMe. Hagenkord has also previously held executive positions with Invitae, Complete Genomics, and iKaryos Diagnostics, which she founded.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.